HealthCare Global Enterprises Ltd. HCG
NSE · India · Health Services
INR 662.70-3.35 (-0.50%)
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
HealthCare Global Enterprises (HCG), Bengaluru, has begun treating cancer patients using Karnataka's first Elekta Unity MR-Linac. With this milestone, HCG opens up access to MR-guided adaptive radiation therapy for patients across Karnataka and neighbouring regions, bringing one of the most advanced approaches in radiation oncology closer to those who need it.
Company reports 13% YoY revenue increase to INR 6,951 million, with adjusted EBITDA up 20% and a confident path toward 24-25% long-term margins.
HealthCare Global Enterprises Ltd (NSE:HCG) reports robust FY26 growth with strategic expansions, despite facing challenges from low-margin business reductions and geopolitical impacts.
HealthCare Global Enterprises Ltd (NSE:HCG) reports robust financial performance with a 13.4% revenue increase and unveils future growth strategies amidst market challenges.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.